bluebird bio Inc (BLUE)
1.28
-0.08
(-6.23%)
USD |
NASDAQ |
Mar 28, 16:00
1.265
-0.02
(-1.17%)
After-Hours: 20:00
bluebird bio Cash from Operations (TTM): -277.48M for Sept. 30, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
September 30, 2023 | -277.48M |
June 30, 2023 | -292.66M |
March 31, 2023 | -314.30M |
December 31, 2022 | -352.95M |
September 30, 2022 | -436.40M |
June 30, 2022 | -506.32M |
March 31, 2022 | -557.61M |
December 31, 2021 | -635.64M |
September 30, 2021 | -651.11M |
June 30, 2021 | -652.95M |
March 31, 2021 | -467.56M |
December 31, 2020 | -470.35M |
September 30, 2020 | -474.13M |
June 30, 2020 | -438.74M |
March 31, 2020 | -616.35M |
December 31, 2019 | -564.38M |
September 30, 2019 | -535.14M |
June 30, 2019 | -496.23M |
March 31, 2019 | -458.76M |
December 31, 2018 | -413.43M |
September 30, 2018 | -379.07M |
June 30, 2018 | -360.94M |
Date | Value |
---|---|
March 31, 2018 | -314.07M |
December 31, 2017 | -280.55M |
September 30, 2017 | -254.28M |
June 30, 2017 | -237.38M |
March 31, 2017 | -228.18M |
December 31, 2016 | -189.65M |
September 30, 2016 | -153.63M |
June 30, 2016 | -143.25M |
March 31, 2016 | -111.04M |
December 31, 2015 | -98.43M |
September 30, 2015 | -81.01M |
June 30, 2015 | -72.71M |
March 31, 2015 | -71.92M |
December 31, 2014 | -59.69M |
September 30, 2014 | -49.48M |
June 30, 2014 | -37.57M |
March 31, 2014 | -34.50M |
December 31, 2013 | 43.45M |
September 30, 2013 | 42.27M |
June 30, 2013 | 46.91M |
March 31, 2013 | 51.17M |
December 31, 2012 | -21.04M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-652.95M
Minimum
Jun 2021
-277.48M
Maximum
Sep 2023
-484.16M
Average
-474.13M
Median
Sep 2020
Cash from Operations (TTM) Benchmarks
Vertex Pharmaceuticals Inc | 3.537B |
Agenus Inc | -224.20M |
Neurocrine Biosciences Inc | 389.90M |
Motus GI Holdings Inc | -11.19M |
AIM ImmunoTech Inc | -17.58M |